Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -5.34% | -12.15% | -6.71% | 4.59% | 16.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.34% | -12.15% | -6.71% | 4.59% | 16.04% |
| Cost of Revenue | -5.70% | -10.18% | -0.96% | 13.36% | 25.89% |
| Gross Profit | -5.09% | -13.53% | -10.53% | -1.06% | 9.76% |
| SG&A Expenses | -9.84% | -12.70% | -9.80% | -7.01% | -1.85% |
| Depreciation & Amortization | 5.94% | -0.47% | -3.59% | -4.52% | -4.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.19% | -12.23% | -6.61% | 0.66% | 8.62% |
| Operating Income | 17.57% | -11.52% | -7.47% | 50.63% | 157.79% |
| Income Before Tax | 465.71% | 246.00% | 143.07% | 102.10% | 89.93% |
| Income Tax Expenses | 94.48% | 86.86% | 100.51% | 105.11% | -398.76% |
| Earnings from Continuing Operations | -39.42% | -53.23% | -66.61% | -117.53% | 153.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.42% | -53.23% | -66.61% | -117.53% | 153.84% |
| EBIT | 17.57% | -11.52% | -7.47% | 50.63% | 157.79% |
| EBITDA | 14.72% | -7.81% | -5.70% | 29.10% | 69.97% |
| EPS Basic | -51.61% | -62.17% | -78.32% | -119.71% | 154.64% |
| Normalized Basic EPS | 1,136.04% | 1,021.71% | 251.18% | 140.91% | 89.68% |
| EPS Diluted | -44.71% | -55.41% | -71.15% | -161.80% | 147.11% |
| Normalized Diluted EPS | 1,110.00% | 994.38% | 246.58% | 139.20% | 89.52% |
| Average Basic Shares Outstanding | 15.74% | 21.08% | 16.64% | 11.75% | 6.38% |
| Average Diluted Shares Outstanding | 13.59% | 18.68% | 14.34% | 9.58% | 9.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |